T1	Participants 52 97	patients with pulmonary arterial hypertension
T2	Participants 172 223	patients with pulmonary arterial hypertension (PAH)
T3	Participants 895 964	98 randomized patients, 61% were WHO functional class II at baseline.
T4	Participants 1654 1719	PAH patients who were mostly WHO functional class II at baseline.
